The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment

Table 4

The influence of SLC22A1 and SLC47A1 polymorphisms on BMI and lipid profile.

Polymorphism		BMI; median; (25–75%)	𝑃^a	Total cholesterol; median; (25–75%)	𝑃^a	HDL cholesterol; median; (25–75%)	𝑃^a	LDL cholesterol; median; (25–75%)	𝑃^a	TAG; median; (25–75%)	𝑃^a
SLC47A1; rs2289669	GG	30.0; (28.0–33.0)	0.835	4.6; (3.9–5.5)	0.018	1.2; (1.0–1.4)	0.683	2.7; (2.0–3.5)	0.070	1.7; (1.3–2.7)	0.562
	GA	29.0; (28.0–34.5)		4.5; (3.6–5.0)		1.1; (1.0–1.5)		2.4; (1.9–3.2)		1.6; (1.2–2.4)
	AA	29.0; (26.0–35.0)		4.0; (3.4–4.2)		1.1; (1.0–1.3)		2.1; (1.9–2.5)		1.5; (1.4–1.9)
SLC22A1; rs628031	GG	29.0; (28.0–34.0)	0.387	4.5; (3.8–5.6)	0.711	1.2; (1.0–1.4)	0.096	2.5; (2.0–3.5)	0.365	1.5; (1.2–2.2)	0.569
	GA	30.0; (27.1–32.0)		4.4; (3.8–5.3)		1.2; (1.0–1.5)		2.4; (1.9–3.2)		1.8; (1.3–2.5)
	AA	32.5; (28.3–34.0)		4.2; (3.7–4.9)		1.1; (0.9–1.3)		2.4; (1.7–3.1)		1.7; (1.2–2.9)

aCalculated using Kruskal-Wallis test.